Robotic-surgery expert Intuitive Surgical
For the first quarter, your average analyst expects to see earnings of $3.14 per share on $465 million in sales. That would amount to 21% year-over-year earnings growth on 20% stronger revenue.
Not too shabby, except that Intuitive tends to grow even faster than that:
To be fair to the startled analysts, Intuitive's management likes to set expectations pretty low. The long-term target for revenue growth is a modest 17% to 19% a year. That's a pretty modest goal given the enormous growth potential that's still ahead of this innovator.
For example, Intuitive is growing like gangbusters overseas. As Fellow Fool Eric Bleeker shows, sector rivals such as Boston Scientific
Intuitive Surgical's business moat is safe as houses filled with razor wire and starving zombies swimming in superheated aqua regia -- not to mention patents and FDA approvals. The company has no serious head-to-head rivals, though sector neighbors MAKO Surgical
That's why Intuitive is not only my largest personal holding but also by far the most successful stock in my CAPS portfolio. That CAPScall stays firmly in place because I'm certain that the company still has its best days ahead of it. The Fool's expert on all things medical, Brian Orelli, says that Intuitive Surgical is the best stock for your IRA portfolio, and this Motley Fool special free report discusses how robotic surgery is the wave of the future. I expect Intuitive to keep beating analysts about the head and neck with its massive growth.